Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q1 FY20 Earnings Presentation
25 slides from Dishman Carbogen Amcis's earnings presentation, Aug 14, 2019
Slide 1: Cover letter to stock exchanges
dish man 14th August, 2019 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, "Exchange Plaza", C-1, Block G, Mumbai - 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051. Ref.: Scr
Slide 2: Dishman Carbogen Amcis Limited Q1 FY20 Results Update
DISHMAN CARBOGEN AMCIS LIMITED Q1 FY20 RESULTS UPDATE AUGUST 2019 1
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward looking statements, which may include statements relating to future results of
Slide 4: Discussion Summary
DISCUSSION SUMMARY v Q1 FY20 RESULTS UPDATE v INDUSTRY OVERVIEW v COMPANY OVERVIEW 3
Slide 5: Q1 FY20 Results Update
Q1 FY20 RESULTS UPDATE 4
Slide 6: Q1 FY20 Result Highlights
Q1 FY20 RESULT HIGHLIGHTS In Rs Mn REVENUES EBITDA & EBITDA MARGIN * 25.0% 5,219 22.9% 4,822 1,208 1,194 8.2% Q1 FY19 Q1 FY20 Q1 FY19 Q1 FY20 ADJUSTED PBT # & PBT MARGIN CASH PAT @ & CASH EPS 16.6% 13.1% 5.6 5.7 802 881 930 683 Q1 FY19 Q1 FY20 Q1 FY19 Q1 FY20 * EBITDA excluding other income @ Cash P
Slide 7: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (In Rs. Mn.) Q1 FY20 Q1 FY19 YoY % Q4 FY19 QoQ % FY19 Revenue from Operations 5,012.9 4,487.3 11.7% 6,114.2 -18.0% 19,199.4 Other Operating Income 206.1 335.1 -38.5% 383.0 -46.2% 1,386.6 Total Revenues 5,219.0 4,822.4 8.2% 6,497.2 -19.7% 20,586.0 COGS 1,302.6 1
Slide 8: Q1 FY20 Segment-wise Revenue Analysis
Q1 FY20 SEGMENT-WISE REVENUE ANALYSIS In Rs Mn Revenues – Segment wise Breakup Q1 FY20 Q1 FY19 YoY% FY19 CRAMS CRAMS – India 767.3 598.2 28.3% 3,405.8 CRAMS – CAAG+RIOM* 2,631.7 2,643.5 -0.4% 10,396.2 CRAMS – UK 375.3 132.0 184.3% 905.5 CRAMS Total 3,774.4 3,373.7 11.9% 14,707.6 Marketable Molecules
Slide 9: Q1 FY20 Segment-wise Revenue Break-up
Q1 FY20 SEGMENT-WISE REVENUE BREAK-UP Total Operating Revenue – Q1 FY20 CRAMS – 75.3% Marketable Molecules – 24.7% 10% 59% 70% 100% 41% 20% CRAMS - India CRAMS - CAAG+RIOM* CRAMS - UK Carboge n Amcis BV** Others# * CRAMS – CAAG+RIOM includes DCAL’s Switzerland (Carbogen Amcis AG) and France (Riom) f
Slide 10: Q1 FY20 Segment-wise Margin Analysis
Q1 FY20 SEGMENT-WISE MARGIN ANALYSIS EBITDA Margin % – Segment wise Q1 FY20 Q1 FY19 FY19 CRAMS CRAMS – India 51.6% 55.6% 57.1% CRAMS – CAAG+RIOM* 18.2% 19.1% 19.8% CRAMS – UK 11.9% 15.1% 24.1% Marketable Molecules Carbogen Amcis BV** 30.4% 44.9% 40.9% Others# 9.8% 10.8% 11.5% * CRAMS – CAAG+RIOM inc
Slide 11: Q1 FY20 Result Highlights
Q1 FY20 RESULT HIGHLIGHTS Financial Highlights: q Total Revenues increased by 8.2% YoY to Rs 5,219.0 mn in Q1 FY 2020. v CRAMS revenue grew by 11.9% YoY primarily due to increase in development and commercial orders. v CRAMS India revenue grew by 28.3% YoY mainly due to increase in sales of certain
Slide 12: Improving Margin Profile Across Key Segments
IMPROVING MARGIN PROFILE ACROSS KEY SEGMENTS Segment-Wise EBITDA Margin Trend 56.2% 57.1% 54.1% 50.1% 38.2% 40.9% 33.2% 29.8% 21.3% 20.2% 19.8% 18.6% FY16 FY17 FY18 FY19 CRAMS - India CRAMS - CAAG + RIOM Carbogen Amcis BV 11
Slide 13: Company Overview
COMPANY OVERVIEW 12
Slide 14: Brief Profile
BRIEF PROFILE BUSINESS OVERVIEW KEY STRENGTHS FINANCIAL OVERVIEW • Integrated CRAMS company with strong • Preferred global outsourcing partner with • Consolidated Revenues, EBITDA and capabilities right from process research & capabilities across the entire CRAMS value Adj. PAT of Rs 20,586 Mn, Rs 5
Slide 15: Manufacturing Facilities – Robust R&D Capabilities
MANUFACTURING FACILITES – ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, TGA, WHO, KFDA Superior Chemistry Skills & Capabilities • 28 dedicated R&D labs with multiple-shift R&D operations, including HIPO labs • 25 multi-purpose facilitie
Slide 16: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY TO LARGE SCALE INTEGRATED ACROSS STRONG CHEMISTRY CLIENTS WITH GLOBAL MANUFACTURING THE VALUE CHAIN CAPABILITIES PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 17: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER Integrated CRAMS Player – Strong Capabilities across the Value Chain Carbogen Amcis (CA) Strong Research Capabilities EARLY STAGE LATE STAGE COMMERCIAL SUPPLY • Focus is on supporting the Process research and API supply to Process development and Secure, value-for-money devel
Slide 18: Cutting-Edge HIPO Capabilities
CUTTING-EDGE HIPO CAPABILITIES World Class HIPO capabilities • Facilities range from laboratory scale for process research and development to large scale manufacturing on 8,000 L scale, with an ability to handle the highest category IV compounds (high toxicity levels). • State-of-the-art containment
Slide 19: Corporate Restructuring
CORPORATE RESTRUCTURING SCHEME OF ARRANGEMENT & AMALGAMATION IMPACT OF MERGER • The Board Of Directors approved the Scheme of Arrangement and • The amalgamation has been accounted under the "Purchase Method" as per Amalgamation on 24th February 2016, which involves merger of Dishman AS14. Pharmaceut
Slide 20: Shareholding Structure
SHAREHOLDING STRUCTURE % Shareholding – June 2019 Public, 17.61 Promoter & Promoter Institutions, Group, 61.40 20.99 Key Institutional Investors as at June - 19 % Holding TATA MF 3.16% IDFC MF 2.85% ICICI Prudential MF 2.75% Aditya Birla SunLife MF 1.38% Government Pension Fund Global 1.40% Source:
Slide 21: Industry Overview
INDUSTRY OVERVIEW 20
Slide 22: Global Spending on Medicine
GLOBAL SPENDING ON MEDICINE As per BRC Report, Contract Research Outsourcing (CRO) Market to reach $44.4bn by 2021 • Oncology is expected to be the most critical therapeutic segment driving the global spend on medicine in future. Outlook of Leading Therapy Areas Spending and Growth, Constant US $ Bn
Slide 23: Global Medicines in Late Stage Development
GLOBAL MEDICINES IN LATE STAGE DEVELOPMENT Oncology 29% 13% • Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies. CNS 11% 7% • Around 29% of the Phase II / III clinical trials are in the Oncology segment. 6% Anti-Infectives / Antivirals 9% • Oncology (can
Slide 24: Global Oncology Medicine Pipeline
GLOBAL ONCOLOGY MEDICINE PIPELINE Ø 710 Molecules in late-stage development and 700+ companies with late-stage oncology drugs. Ø Top companies with combined sales of $10bn+ have ~40% of their product pipeline in oncology. Ø 455 smaller companies with 90%+ product pipeline in oncology, are involved i
Slide 25: For Further Queries
FOR FURTHER QUERIES: Mr. Harshil Dalal Senior Vice President – Accounts & Finance Email: harshil.dalal@dishmangroup.com Mr. Nachiket Kale / Chintan Mehta IR Consultants Contact: +91 9920940808 / +91 9892183389 Email:dishman@dickensonworld.com 24
Dishman Carbogen Amcis — Q1 FY20 Earnings Presentation on 6ix